A recent meta-study on the cardiotoxicity of anthracyclines (Nesser et al., 2009) showed that overweight and obesity were significantly associated with the risk of cardiotoxicity with anthracyclines and anti-Her-2 targeted therapy, consistent with the increased risk of higher body mass index in patients receiving anthracyclines and anthracyclines followed by trastuzumab in this study. This evidence concerns the gene ERBB2 and Obesity.